Back
63· Active
Health & Science3h 52m ago
Germany’s medicines regulator green-lit a psilocybin compassionate use program, the first such pathway in the European Union.
Archive Window: 7 Days Left
Germany (Berlin, Mannheim), European Union
Who
Lea Mertens, Andrea Jungaberle
What
Germany’s medicines regulator green-lit a psilocybin compassionate use program, the first such pathway in the European Union.
When
Tue, 16 Jun 2026 10:11:55 GMT · 3h 52m ago
Where
Germany (Berlin, Mannheim), European Union ·
Why
The program aims to provide access to psilocybin for patients outside of clinical trials, based on research from the EPIsoDE study.
The Frontline Impact
How this affects you
This program marks a significant step in the EU for psychedelic-assisted therapy. The focus on public and private insurance coverage could set a precedent for broader accessibility of psilocybin treatment, potentially benefiting a wider range of patients with mental health conditions. While still in early stages, successful implementation and insurance integration could influence similar initiatives across Europe and beyond.
Story chain
4 events in this thread- Health & Science3h 52m agoGermany's psilocybin compassionate use program is underway with early patient experiences and progress in securing insurance coverage.Open article
- Health & Science3h 52m agoGermany's medicines regulator green-lit a psilocybin compassionate use program, the first in the European Union.Open article
- Health & Science3h 52m agoGermany has green-lit the EU’s first psilocybin compassionate use program, with two centers, OVID Clinic Berlin and CIMH Mannheim, permitted to offer dosing.Open article
- Currently Reading3h 52m agoGermany’s medicines regulator green-lit a psilocybin compassionate use program, the first such pathway in the European Union.